ここまできて、何回かエラー画面に飛ばされたけど、上手くいってたのに1番最後尾に並ばせるのは人の心無さすぎじゃないですかフェルメール展さん？？？？？ 私ちゃんとサイトも開いてたし何もおかしな所触ってませんよ？？？

$RCKT sold PPRV for $180M. total cash to $322.6M, but stock is trading under cash value. I do not get it.

Queria acompanhar, mas não liberaram o pprv #BBB26

O problema do ranço da Samira é que a Ana vai perdendo o brilho, pois vemos ela como alguém inteligente e sensata. Nem consigo mais assistir a Ana no pprv por causa da assombração da Samira. Parece um encosto. Tomara que ela caia no paredão logo.

Rare Disease Week is a reminder of what patient voices can achieve... This year, the rare disease community helped secure reauthorization of the Rare Pediatric Disease Priority Review Voucher (PPRV) program - preserving a critical pathway for the development of new medicines and treatments. Because patients raise their voices, progress continues. #RareDiseaseWeek #RDW26

KKKKKKKKKKKKK a AP chamando a marcielle e a Maxiane agora no pprv de MM KKKKKKKKKKKKK eu amo essa velha ❤️ #BBB26

Check out our new paper in Virulence. We showed that the cytokine IL-10 participates in the immunosuppression produced by the ruminant virus PPRV in goat dendritic cells. 🐐🦠 @CISA_INIA_CSIC @INIA_es @CSIC tandfonline.com/doi/full/10.…

Stories like that of Sammy Brazzo illuminate why the recent reauthorization of the #PPRV program is critical to the rare pediatric community. This bipartisan program will continue to catalyze investment in rare pediatric disease research - accelerating the development of therapies for children who cannot afford to wait. This is Sammy's #MissionMoment.

eu passo o dia trocando a câmera pq parece que o câmera o pprv é do time da trindade q ódio #BBB26

$OCGN #OCUGEN 👇 👇 👇 #PPRV.....Congress get it done!!! linkedin.com/posts/biotechno…

As Congress considers PPRV reauthorization, these courageous kids aren’t taking no for an answer. They’re urging congressional leaders to reauthorize the PPRV program and restore hope for the 15 million kids living with rare diseases in the U.S. Learn more: bio.org/prv

Jilani’s journey shows why funding for rare disease research is critical to the rare pediatric disease community. And it’s why millions of pediatric patients and families are urging the reauthorization of the #PPRV. Learn more: bio.org/prv

In BIO’s PPRV story series, hear from the courageous children living with rare diseases - who are some of the biggest advocates for the rare pediatric disease community: bio.org/prv

Speaking up for millions of pediatric patients across the U.S., meet the courageous kids and families who are urging Congress to reauthorize the PPRV: bio.org/prv

The Rare Pediatric Disease Priority Review Voucher (PPRV) Program offers millions of children like Juliet a critical lifeline of hope. Learn more: bio.org/prv

He called for bold action to secure the future of U.S. ##biotechnology innovation through: 1️⃣ Strengthening the FDA’s role as the global gold standard, ensuring predictability, scientific integrity, and confidence in the U.S. regulatory system. 2️⃣ Rebuilding America’s biotechnology #manufacturing base, creating high-quality jobs and resilient supply chains. 3️⃣ Reauthorizing the Rare Pediatric Disease Priority Review Voucher (#PPRV) program, a historically bipartisan vehicle of hope and treatment for millions of children and families affected by rare diseases. 4️⃣ Expanding the biotech #workforce, ensuring that America’s talent pipeline remains the strongest in the world. As John reminded the Committee - maintaining U.S. #biotech leadership is not guaranteed - it demands investment, coordination, and trust in the science that drives progress. When America leads in biotechnology, we lead in health, security, and hope for millions of patients and families across America - and the world. Read the full testimony on bio.org: bio.org/letters-testimony-co…

BIO’s Board of Directors gathered in Washington this week for two days of advocacy-packed discussions focused on advancing U.S. biotechnology leadership and protecting patients across America. Today, BIO Board members traveled to Capitol Hill to meet with congressional leaders on critical #biotech issues - from the devastating implications of Most Favored Nation pricing, to the urgent need to reauthorize the Pediatric Priority Review Voucher (PPRV) program, to policies supporting domestic manufacturing and U.S. biosecurity. Together, BIO member companies are committed to driving biotechnology’s competitiveness - and ensuring patients remain at the center of innovation and advocacy. Learn more about BIO’s advocacy on these issues: The Cost of PRV Inaction: bio.org/prv It's Time to Simplify the System (Most Favored Nation): bio.org/putting-americans-fi…

We were honored to host Sammy, Kelly and their family, who are featured in this powerful opinion piece reflecting the urgency and hope behind efforts to reauthorize the Pediatric Priority Review Voucher (PPRV) program. The program, which expired in December 2024, has helped advance treatments for #rarediseases by offering incentives for drug development. The need for renewal is urgent, as more than 90% of known rare diseases, including LGMD2I/R9, still have no approved treatment. Legislative tools like the PPRV help make a difference for families facing these challenges. pennlive.com/opinion/2025/10…

Children living with rare disease are assigning congressional leaders with a very important task. Learn more about the importance - and longstanding bipartisan support - of reauthorizing the PPRV program: bio.org/prv